Sneha Phadke, DO, MPH, discusses the benefit associated with treatment consisting of the antibody drug conjugates sacituzumab govitecan in hormone receptor-positive/HER2-negative breast cancer.
Sneha Phadke, DO
Advertisement
Articles by Sneha Phadke, DO
Sneha Phadke, DO, MPH, discusses sequencing treatment with antibody drug conjugates in hormone receptor-positive/HER2-negative breast cancer, as well as questions remaining within this space.
Cyclin-dependent kinase (CDK) 4/6 inhibitors are novel agents that have shown promising results in the treatment of breast cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Docetaxel Remains Unbeaten in Immunotherapy-Refractory NSCLC
2
Ris-Rez Meets Phase 3 Efficacy End Point for R/R Osteosarcoma
3
Long-Term Data Refine the Role of Immunotherapy Across Early-Stage NSCLC Settings
4
Cretostimogene Grenadenorepvec Elicits Durable Complete Responses and Bladder Preservation in BCG-Unresponsive NMIBC
5